A Phase 1/2 interventional study of IMSA101 and Immune checkpoint inhibitor (ICI) in Solid Tumor, Adult, sponsored by ImmuneSensor Therapeutics Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by ImmuneSensor Therapeutics Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)
This is an open-label, dose escalation (Phase I), and dose expansion (Phase IIA) study designed to evaluate safety and efficacy of IMSA101 alone or in combination with an ICI (Phase I and II). Therefore, the study will be conducted in 2 phases. The dose of IMSA101 in Phase IIA will be based on the monotherapy and combination Recommended Phase 2 Doses (RP2Ds) from Phase I.
The following methodology applies to all patients (unless otherwise indicated):
ImmuneSensor Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically documented locally advanced or solid tumor to or otherwise ineligible for treatment with standard-of-care agents/regimens, including but not limited to:
Evaluable or as follows:
Acceptable organ and marrow function as defined below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Dose escalation design in which administered dose levels of IMSA101 as monotherapy will be escalated stepwise in successive cohorts of 3 to 6 patients per dose group (using a standard 3+3 study design) of IMSA101 until the RP2D or maximum tolerated dose (MTD) level is identified. * The first patient enrolled in each dose level must complete the first two weeks of Cycle 1 prior to enrolling the second and third patients. * Dose levels to be evaluated include (although not necessarily limited to) 100 µg (representing 1/60th of the pre-clinical Highest Non-Severely Toxic Dose \[HNSTD\] dose), 200 µg, 400 µg, 800 µg, and 1,200 µg.
Drug: IMSA101
* Ph I combination dosing of IMSA101 shall be evaluated upon satisfaction of the following criteria: * A given dose level (combo dose level 1) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT). * The next higher dose level (combo dose level 2) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT). * The dose level (combo dose level 1) is found to demonstrate adequate IMSA101 pharmacodynamic (PD) activity based on exploratory endpoints. * Eligible patients shall have demonstrated RECIST stable disease through ≥ 4 consecutive cycles of an approved PD-1/PD-L1-targeted ICI with no Grade ≥ 3 CTCAE events considered to be drug-related. * Safety evaluations and dose escalation of IMSA101 administered in combination with current therapy shall proceed in a manner consistent with monotherapy escalation and shall proceed independently of monotherapy dose escalation.
Drug: IMSA101 · Drug: Immune checkpoint inhibitor (ICI)
* This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as monotherapy * Tumor type to be evaluated will be identified prior to Phase IIA commencement and will be documented in a protocol amendment.
Drug: IMSA101
* This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with PD-1/PD-L1 targeted immune checkpoint inhibitors. * This arm shall include a safety run-in of 5-10 patients. * Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment.
Drug: IMSA101 · Drug: Immune checkpoint inhibitor (ICI)
* This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with non-PD-1/PD-L1-targeted immuno-oncology (IO) drugs approved by the FDA. * This arm shall include a safety run-in of 5-10 patients. * Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment..
Drug: IMSA101 · Drug: Immuno-oncology (IO) therapy
IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
Administered according to product label
Administered according to product label
Number of Participants With Dose-Limiting Toxicities
Highest dose level of IMSA101 at which no more than 1 out of 6 patients experienced a dose limiting toxicity (DLT) during the first cycle (28 days) of therapy.
Time frame: Cycle 1 (28 days) of therapy
Best Overall Response
The sum of number of patients with best overall response (complete response, partial response, stable disease or progressive disease) as per RECIST v1.1 until End of Treatment. Tumor response was evaluated at the end of each even numbered cycle (eg. Cycle 2, Cycle 4, etc.) until End of Treatment.
Time frame: 9 months
| Milestone | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 μg | Monotherapy 1200 μg | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 2400 μg |
|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 4 | 4 | 7 | 4 | 7 | 7 |
| Completed | 3 | 2 | 3 | 2 | 4 | 4 | 4 | 5 |
| Not completed | 1 | 1 | 1 | 2 | 3 | 0 | 3 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 2 | 1 | 0 | 1 | 0 |
| Withdrew: Consent withdrawn | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 1 |
| Withdrew: Patient in hospice | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Continuing on expanded access | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Highest dose level of IMSA101 at which no more than 1 out of 6 patients experienced a dose limiting toxicity (DLT) during the first cycle (28 days) of therapy.
| Participants | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 μg | Monotherapy 1200 μg | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 2400 μg |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
The sum of number of patients with best overall response (complete response, partial response, stable disease or progressive disease) as per RECIST v1.1 until End of Treatment. Tumor response was evaluated at the end of each even numbered cycle (eg. Cycle 2, Cycle 4, etc.) until End of Treatment.
| Participants | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 μg | Monotherapy 1200 μg | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 2400 μg |
|---|---|---|---|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial Response | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Stable Disease | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| Progressive Disease | 4 | 3 | 2 | 2 | 6 | 3 | 4 | 3 |
| Not Evaluable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over 9 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Monotherapy 100 μg | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Monotherapy 200 μg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Monotherapy 400 μg | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| Monotherapy 800 | 2/4 (50%) | 3/4 (75%) | 3/4 (75%) |
| Monotherapy 1200 | 1/7 (14.3%) | 1/7 (14.3%) | 7/7 (100%) |
| Combination Therapy 800 μg | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Combination Therapy 1200 μg | 1/7 (14.3%) | 5/7 (71.4%) | 7/7 (100%) |
| Combination Therapy 24000 μg | 0/7 (0%) | 5/7 (71.4%) | 7/7 (100%) |
| Event | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 | Monotherapy 1200 | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 24000 μg |
|---|---|---|---|---|---|---|---|---|
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 1/3 | 0/4 | 0/4 | 0/7 | 0/4 | 0/7 | 0/7 |
| Disease progressionGeneral disorders | 0/4 | 0/3 | 0/4 | 1/4 | 1/7 | 0/4 | 2/7 | 0/7 |
| DysphagiaGastrointestinal disorders | 0/4 | 0/3 | 0/4 | 1/4 | 0/7 | 0/4 | 0/7 | 0/7 |
| Inguinal herniaGastrointestinal disorders | 1/4 | 0/3 | 0/4 | 0/4 | 0/7 | 0/4 | 0/7 | 0/7 |
| Malignant bowel obstructionGastrointestinal disorders | 0/4 | 0/3 | 1/4 | 0/4 | 0/7 | 0/4 | 0/7 | 0/7 |
| PyrexiaGeneral disorders | 1/4 | 0/3 | 0/4 | 0/4 | 0/7 | 0/4 | 0/7 | 0/7 |
| Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/3 | 0/4 | 1/4 | 0/7 | 0/4 | 0/7 | 0/7 |
| Malignant pleural effusionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/4 | 0/3 | 0/4 | 0/4 | 0/7 | 0/4 | 0/7 | 0/7 |
| PneumoniaInfections and infestations | 1/4 | 0/3 | 0/4 | 0/4 | 0/7 | 0/4 | 0/7 | 0/7 |
| Extradural haematomaInjury, poisoning and procedural complications | 0/4 | 0/3 | 1/4 | 0/4 | 0/7 | 0/4 | 0/7 | 0/7 |
| Event | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 | Monotherapy 1200 | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 24000 μg |
|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 1/4 | 3/3 | 3/4 | 1/4 | 3/7 | 1/4 | 3/7 | 5/7 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 3/3 | 0/4 | 0/4 | 1/7 | 1/4 | 3/7 | 4/7 |
| Injection site painGeneral disorders | 1/4 | 1/3 | 1/4 | 0/4 | 5/7 | 3/4 | 1/7 | 0/7 |
| VomitingGastrointestinal disorders | 2/4 | 0/3 | 0/4 | 0/4 | 1/7 | 0/4 | 5/7 | 1/7 |
| PyrexiaGeneral disorders | 2/4 | 0/3 | 0/4 | 0/4 | 0/7 | 0/4 | 2/7 | 4/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/4 | 0/3 | 2/4 | 0/4 | 1/7 | 1/4 | 3/7 | 4/7 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 0/3 | 0/4 | 0/4 | 1/7 | 1/4 | 2/7 | 2/7 |
| AstheniaGeneral disorders | 0/4 | 0/3 | 2/4 | 0/4 | 0/7 | 0/4 | 1/7 | 3/7 |
| DysphagiaGastrointestinal disorders | 0/4 | 0/3 | 0/4 | 2/4 | 0/7 | 0/4 | 0/7 | 1/7 |
| HeadacheNervous system disorders | 0/4 | 1/3 | 2/4 | 0/4 | 1/7 | 0/4 | 3/7 | 3/7 |
Patients who received at least 1 dose of IMSA101.
| Age, Categorical(Participants) | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 μg | Monotherapy 1200 μg | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 2400 μg | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 1 | 1 | 3 | 1 | 7 | 3 | 22 |
| >=65 years | 1 | 0 | 3 | 3 | 4 | 3 | 0 | 4 | 18 |
| Age, Continuous(years) | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 μg | Monotherapy 1200 μg | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 2400 μg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 56.5 ± 12.01 | 53.7 ± 2.08 | 66.5 ± 4.12 | 64.8 ± 6.95 | 65.0 ± 14.29 | 74.0 ± 11.34 | 50.3 ± 10.89 | 63.0 ± 21.53 | 61.4 ± 14.12 |
| Sex: Female, Male(Participants) | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 μg | Monotherapy 1200 μg | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 2400 μg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 3 | 2 | 5 | 2 | 3 | 6 | 22 |
| Male | 3 | 3 | 1 | 2 | 2 | 2 | 4 | 1 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 μg | Monotherapy 1200 μg | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 2400 μg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 0 | 0 | 3 | 2 | 7 |
| Not Hispanic or Latino | 3 | 2 | 3 | 3 | 7 | 3 | 4 | 5 | 30 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Monotherapy 100 μg | Monotherapy 200 μg | Monotherapy 400 μg | Monotherapy 800 μg | Monotherapy 1200 μg | Combination Therapy 800 μg | Combination Therapy 1200 μg | Combination Therapy 2400 μg | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| White | 3 | 1 | 1 | 2 | 5 | 4 | 4 | 6 | 26 |
| More than one race | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Unknown or Not Reported | 1 | 1 | 2 | 1 | 0 | 0 | 2 | 0 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Sep 2023, 47 months.
Results were first posted in Dec 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: STING Agonist IMSA101
ImmuneSensor Therapeutics Inc.